Table 2.
Summary of study participants’ clinicopathological characteristics
| Clinicopathological data | Study population |
|---|---|
| Pre-operative data | |
| Age at time of surgery (years), mean (SD) | 64.2 (10.1) |
| Time from surgery to study participation (months), mean (SD) | 35.6 (17.7) |
| Ethnic origin (%) | |
| White | 186 (93) |
| Non-white | 14 (7) |
| Smoking status (%) | |
| Never | 119 (59.5) |
| Current | 16 (8) |
| Ex-smoker | 65 (32.5) |
| BMI at surgery (kg/m2), mean (SD) | 27.5 (5.4) |
| Location of tumour on pre-operative imaging (%) | |
| Upper outer | 109 (54.5) |
| Central | 8 (4) |
| Lower inner | 27 (13.5) |
| Lower outer | 21 (10.5) |
| Upper inner | 35 (17.5) |
| Ultrasound size (mm), mean (SD) | 13.9 (8.6) |
| Mammographic size (mm), mean (SD) | 16.26 (10.88) |
| Intra-operative data | |
| Type of surgery (%) | |
| WLE | 181 (90.5) |
| Other complex breast conservation | 19 (9.5) |
| Axillary surgery (%) | |
| Nil | 19 (9.5) |
| SLNB or sampling | 150 (75) |
| ALND | 31 (15.5) |
| Re-excision of margins (%) | |
| No | 169 (84.5) |
| Yes | 31 (15.5) |
| Pathology data | |
| Tumour pathology size including DCIS (mm), mean (SD) | 21.6 (13.1) |
| Weight of specimen (g), median (IQR) | 32.5 (20–49) |
| Adjuvant therapy | |
| Adjuvant chemotherapy (%) | |
| No | 161 (80.5) |
| Yes | 39 (19.5) |
| Endocrine Therapy (%) | |
| No | 30 (15) |
| Yes | 170 (85) |
| Whole breast radiotherapy (%) | |
| No | 0 |
| Yes | 200 (100) |
| Boost radiotherapy (%) | |
| No | 149 (74.5) |
| Yes | 51 (25.5) |